PT  - JOURNAL ARTICLE
AU  - Roberto Ria
AU  - Pellegrino Musto
AU  - Antonia Reale
AU  - Roberto Guariglia
AU  - Giuseppe Iodice
AU  - Franco Dammacco
AU  - Angelo Vacca
TI  - <sup>90</sup>Y-Ibritumomab Tiuxetan as Consolidation Therapy After Autologous Stem Cell Transplantation in Aggressive Non-Hodgkin Lymphoma
AID  - 10.2967/jnumed.110.084376
DP  - 2011 Jun 01
TA  - Journal of Nuclear Medicine
PG  - 891--895
VI  - 52
IP  - 6
4099  - http://jnm.snmjournals.org/content/52/6/891.short
4100  - http://jnm.snmjournals.org/content/52/6/891.full
SO  - J Nucl Med2011 Jun 01; 52
AB  - Targeted radioimmunotherapy with 90Y-labeled ibritumomab tiuxetan is a novel therapeutic approach for CD20-positive relapsed or refractory non-Hodgkin lymphoma (NHL). Methods: Seven consecutive patients with CD20-positive aggressive NHL who did not fully respond to prior myeloablative chemotherapy were enrolled. A 14.8 MBq (0.4 mCi)/kg dose of 90Y-ibritumomab tiuxetan was administered to all patients, and approximately 100 d afterward 18F-FDG PET/CT was performed to assess response. Results: PET/CT showed a complete response in 5 of 7 patients. Of the 2 nonresponsive patients, 1 showed persistent disease and the other progression. Toxicity included thrombocytopenia in all 7 patients and grade IV neutropenic fever in 1 patient. Conclusion: Despite the small series studied, we suggest that radioimmunotherapy is safe for consolidation in patients treated with high-dose chemotherapy for aggressive NHL and may provide clinical benefit in extensively pretreated patients.